Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
CD14	929	IC14	CHEMBL2109330	inhibitor	TdgClinicalTrial, ChemblInteractions
CD14	929	LOVASTATIN	CHEMBL503		NCI	7506029
CD14	929	FLUTICASONE PROPIONATE	CHEMBL1473		PharmGKB

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
CD14	rs2569190	AA + AG	Tumor necrosis factor alpha	efficacy	yes	Cohort with inflammatory bowel disease (IBD). Subcohorts with Crohn's disease (CD) and ulcerative colitis (UC) were also analyzed. Significant results for this genotype seen for the UC cohort. Treatment efficacy was defined using the three-step scale (failure, response, or remission) and reflected the maximum response within 22 weeks after treatment initiation.	Genotypes AA + AG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative as compared to genotype GG.	24776844	1296666832